Group 1 - The company, Zhiyun Health (09955.HK), announced that it will hold a board meeting on August 27, 2025 [1] - The purpose of the meeting is to review and approve the group's interim results for the six months ending June 30, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 於本公告日期，董事會由執行董事匡明先生及左穎暉女士，以及獨立非執行董事洪偉力博士、 張賽音先生及Ang Khai Meng先生組成。 董事長、執行董事兼 首席執行官 匡明 香港，2025年8月15日 （於開曼群島註冊成立的有限公司） （股份代號：9955） 董事會召開日期 智雲健康科技集團*（「本公司」）董事會（「董事會」）兹通告謹定於2025年8月27日 （星期三）舉行董事會會議，以考慮及批准本公司及其附屬公司截至2025年6月 30日止六個月的中期業績及其發佈，以及處理其他事項。 承董事會命 智雲健康科技集團* * 僅供識別 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月6日 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | 本月底法 ...

Core Viewpoint - Zhiyun Health (09955) has demonstrated its strong capabilities in the medical AI sector by successfully entering a key research project focused on generative medical AI models, which is expected to enhance remote decision-making support in healthcare [1] Company Summary - Zhiyun Health's stock rose over 4%, reaching 1.55 HKD with a trading volume of 3.1421 million HKD [1] - The company has been recognized by the Hangzhou Science and Technology Bureau for its project on "Construction of Generative Medical AI Models and Key Technology Research in Remote Decision Support," highlighting its expertise in the medical AI field [1] - The generative medical AI model developed by Zhiyun Health is currently being demonstrated in multiple hospitals across the country, with plans for further expansion in coverage and application depth [1] Industry Summary - The generative medical AI model utilizes IoT perception technology and precise data routing algorithms for medical information transmission, focusing on dynamic data collection for chronic disease patients [1] - The system includes a smart diagnostic assistance system with self-optimizing parameters, enhancing the accuracy and timeliness of remote diagnoses for conditions such as diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease [1] - The overall framework established by the company consists of a closed-loop medical assistance system that integrates data collection, secure transmission, and intelligent decision-making [1]

Core Viewpoint - Zhiyun Health (09955) has demonstrated its strong capabilities in the medical AI sector by successfully entering a key research project focused on generative medical AI models, which is expected to enhance remote decision-making support in healthcare [1] Group 1: Company Developments - Zhiyun Health's stock rose over 4%, reaching HKD 1.55 with a trading volume of HKD 3.1421 million [1] - The company’s project titled "Research on Key Technologies for Constructing Generative Medical AI Models and Their Application in Remote Decision Support" has been officially recognized by the Hangzhou Science and Technology Bureau as part of the 2025 key research plan [1] - The generative medical AI model developed by Zhiyun Health is already being demonstrated in multiple hospitals across the country, with plans for further expansion in coverage and application depth [1] Group 2: Technology and Innovation - The generative medical AI model utilizes IoT perception technology and precise data routing algorithms for medical information transmission [1] - It features a dynamic data collection system for chronic disease patients, establishing a secure transmission channel and data cleaning mechanism for remote healthcare [1] - The intelligent diagnostic assistance system developed by the company employs deep reinforcement learning to optimize decision model parameters in real-time, aiming to improve the accuracy and timeliness of remote diagnoses for conditions such as diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease [1]

Core Viewpoint - Zhiyun Health (09955) has demonstrated its strong capabilities in the medical AI sector by successfully entering a key research project focused on generative medical AI models, as announced by the Hangzhou Science and Technology Bureau [1] Group 1: Company Developments - Zhiyun Health's stock rose over 4%, reaching 1.55 HKD with a trading volume of 3.1421 million HKD [1] - The company’s project titled "Research on Key Technologies for Constructing Generative Medical AI Models and Remote Decision Support" has been officially recognized, highlighting its expertise in the medical AI field [1] Group 2: Technology and Applications - The generative medical AI model developed by Zhiyun Health utilizes IoT perception technology and precise data routing algorithms for medical information transmission [1] - The model has been implemented in several hospitals across the country, with plans for further expansion in coverage and application depth to benefit more medical institutions and patients [1] - The system includes a smart diagnostic assistance feature that optimizes parameters in real-time through deep reinforcement learning, aiming to enhance the accuracy and timeliness of remote diagnoses for chronic diseases such as diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease [1]

Company Overview - Zhiyun Health (09955.HK) is a leading provider of digital chronic disease management solutions in China, established in 2014 [3] - The company offers a comprehensive range of services including hospital SaaS systems, pharmacy SaaS systems, and advanced internet hospital platforms, covering the entire lifecycle of digital chronic disease management [3] - Zhiyun Health serves over 2,700 hospitals and more than 219,000 pharmacies nationwide, integrating upstream and downstream in the industry chain [3] Financial Performance - As of December 31, 2024, Zhiyun Health reported total revenue of 3.488 billion yuan, a year-on-year decrease of 5.49% [2] - The company experienced a net loss attributable to shareholders of 516 million yuan, a significant decline of 59.85% year-on-year [2] - The gross profit margin stood at 24.7%, with a debt-to-asset ratio of 49.63% [2] Market Performance - On July 7, the stock closed at 1.18 HKD per share, marking an increase of 8.26% with a trading volume of 5.484 million shares and a turnover of 6.2606 million HKD [1] - Over the past month, the stock has seen a cumulative increase of 3.81%, but it has declined by 9.17% year-to-date, underperforming the Hang Seng Index by 19.22% [2] Valuation Metrics - Currently, there are no institutional investment ratings for Zhiyun Health [2] - The company's price-to-earnings (P/E) ratio is -1.26, ranking 99th in the industry, while the average P/E ratio for the healthcare equipment and services sector is -2.82 [2] - Comparatively, other companies in the sector have P/E ratios ranging from 0.29 to 5.2 [2]

Core Insights - By 2025, global ESG asset management is expected to exceed $50 trillion, indicating that responsible investment has become mainstream and ESG standards are evolving into a core engine for corporate value reconstruction [1] - Zhiyun Health (09955.HK) was awarded the "Golden Award · ESG Social Responsibility Excellence Enterprise" at the "Gelonghui Mid-term Strategy Summit 2025," highlighting its integration of commercial and social value [1] Group 1: Strategic Upgrades and Innovations - Zhiyun Health's achievements in ESG stem from its deep insights into the healthcare industry and continuous business innovation, particularly in the chronic disease management market, which has significant growth potential [4] - The company has implemented a dual-driven strategy of "AI SaaS + P2M," enhancing overall efficiency in the healthcare ecosystem and establishing a vast network covering 2,738 hospitals and 242,700 pharmacies across China [4][6] - The P2M model has generated total revenue of 320 million yuan and achieved net profit, validating its commercial viability [4] Group 2: Product Development and Market Expansion - Zhiyun Health's self-developed product, Tangjing® Dapagliflozin Tablets, achieved over 10 million yuan in revenue within two months of its launch, indicating strong market penetration potential [5] - The company has entered into exclusive cooperation with Clinect Pty Ltd to introduce a new injectable drug for pulmonary arterial hypertension, expected to maintain rapid growth over the next five years [6] Group 3: Social Responsibility and Community Engagement - The company has implemented a SaaS system that has issued 264 million online prescriptions, benefiting over 38 million users while reducing paper usage and energy consumption [9] - Zhiyun Health actively participates in community activities, such as the "Rural Medical" charity initiative, donating digital health management software and medical equipment to improve healthcare services in underserved areas [10][12] Group 4: Future Outlook and ESG Integration - The integration of technology and a mission for inclusivity positions Zhiyun Health as a leader in sustainable growth, demonstrating that ESG is not merely a moral obligation but a compass for value creation [12] - The company's focus on personalized and precise health management solutions aims to enhance patient quality of life while fulfilling its social responsibilities [6][12]

七成收入靠"AI全病程管理" 商报记者孟佳俊 日前，AI全病程管理服务商微脉，正式向港交所递交招股说明书。 微脉成立于2015年，从最初的挂号平台起步，2018年—2019年成功转型为全病程管理服务商，将核心业 务聚焦于生命周期管理。近年来，微脉紧跟科技发展趋势，持续加码AI领域投入，推出了AI全病程管 理服务模式。目前微脉已跻身中国前三大全病程健康管理服务提供商之列。 记者了解到，微脉的AI全病程管理服务模式类似一位"AI管家"。依托企业自研的AI医疗管理平台，在 诊前阶段，患者能够进行AI预问诊，提前梳理病情信息等；就诊过程中，AI可辅助进行报告解读，帮 助患者更好地理解检查结果等；诊后还能生成个性化的AI健康管理计划，为患者康复提供专业指导。 从数据来看，这一服务模式似乎已成功跑通，还实现了规模化收入。数据显示，2022年至2024年，微脉 的总收入从5.12亿元增长至6.53亿元，增幅达27.5%，而这一增长主要得益于全病程管理服务收入的持 续稳定增长，该业务目前贡献了微脉约70%的收入。 与医院深度合作，是微脉业务模式与商业模式成立的一大基础。截至2024年底，企业已与157家公立医 院共建独家院内 ...

变局加速，机遇涌动！走过充满韧性的 2024 ，中国经济正以"新质生产力"为引擎，在 2025 年深化转型。政策红利持续释放，资本市场改 革深化，外资加速回流人工智能、高端制造、绿色能源等新经济赛道，一场以"新质"为核心的估值重构已然展开。 然而，全球棋局波谲云诡：地缘冲突未息、货币政策分化、供应链重塑承压、多国政治周期叠加 ……如何在百年大变局的深化期，把握未来航 向？ 2025 年下半年，机遇与风险并存，投资者如何优化策略，行稳致远？ 答案，就在深圳！ 2025 年 7 月 4 日 -5 日，格隆汇 2025 中期策略峰会 将再度点亮鹏城！ 我们力邀顶尖思想领袖与实战精英，为您： 深度剖析全球与中国经济核心变局； 前瞻 "新质生产力"驱动的投资主脉络； 拆解复杂环境下的风险与机遇； 共话资本市场改革红利与布局良机； TOP 级机构（合计管理超千亿）分享投资策略和方向。 这是一场智慧碰撞的盛宴，一次拨云见日的集结！ 与远见者同行，与担当者共进！ 会议组成及嘉宾阵容： 7 月 4 日上午 格隆汇 ·中期策略峰会· 2 025 宏观、策略、风投、实业大咖云集，莅临现场共同剖析中国资本市场发展趋势，共同展望 20 ...